pimozide has been researched along with Neoplasm Metastasis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho Han, D; Choi, J; Doo Kim, N; Kim, CH; Kim, SY; Kwon, BM; Lee, YJ; Park, SJ; Yoon, YJ | 1 |
| Baker, MA; Meyskens, FL; Neifeld, JP; Taub, RN; Tormey, DC | 1 |
| Baker, MA; Taub, RN | 1 |
3 other study(ies) available for pimozide and Neoplasm Metastasis
| Article | Year |
|---|---|
Pimozide suppresses cancer cell migration and tumor metastasis through binding to ARPC2, a subunit of the Arp2/3 complex.
Topics: Actin-Related Protein 2-3 Complex; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Movement; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pimozide | 2019 |
Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pimozide; Skin Neoplasms | 1983 |
Treatment of metastatic malignant melanoma with pimozide.
Topics: Administration, Oral; Female; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Middle Aged; Neoplasm Metastasis; Pimozide; Skin Neoplasms | 1979 |